Beigene Ltd (NASDAQ:BGNE) CFO Howard Liang sold 1,800 shares of the firm’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $130.01, for a total transaction of $234,018.00. Following the completion of the sale, the chief financial officer now owns 52,338 shares in the company, valued at approximately $6,804,463.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Howard Liang also recently made the following trade(s):
- On Tuesday, May 21st, Howard Liang sold 23,200 shares of Beigene stock. The stock was sold at an average price of $130.21, for a total transaction of $3,020,872.00.
Shares of BGNE stock traded down $2.24 during trading hours on Friday, reaching $117.93. 384,000 shares of the stock were exchanged, compared to its average volume of 338,612. The stock has a market cap of $5.69 billion, a PE ratio of -9.71 and a beta of 1.07. The company has a current ratio of 7.52, a quick ratio of 7.47 and a debt-to-equity ratio of 0.14. Beigene Ltd has a 12-month low of $105.19 and a 12-month high of $220.10.
A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC boosted its position in Beigene by 2.3% in the 4th quarter. FMR LLC now owns 5,594,173 shares of the company’s stock valued at $784,639,000 after buying an additional 128,072 shares during the period. Hillhouse Capital Advisors Ltd. bought a new stake in shares of Beigene in the 4th quarter valued at about $622,467,000. BlackRock Inc. raised its holdings in shares of Beigene by 2.5% in the 1st quarter. BlackRock Inc. now owns 1,923,650 shares of the company’s stock valued at $253,922,000 after purchasing an additional 46,540 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in shares of Beigene by 0.5% in the 4th quarter. Canada Pension Plan Investment Board now owns 1,121,497 shares of the company’s stock valued at $157,288,000 after purchasing an additional 5,627 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Beigene by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,064,236 shares of the company’s stock valued at $183,283,000 after purchasing an additional 105,702 shares in the last quarter. 81.37% of the stock is owned by institutional investors.
Several brokerages have recently weighed in on BGNE. Zacks Investment Research upgraded shares of Beigene from a “sell” rating to a “hold” rating in a research note on Tuesday, May 7th. Maxim Group set a $170.00 price target on shares of Beigene and gave the stock a “buy” rating in a research note on Thursday, February 28th. ValuEngine downgraded shares of Beigene from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 15th. Morgan Stanley lifted their price target on shares of Beigene from $200.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, May 14th. Finally, Piper Jaffray Companies dropped their price objective on shares of Beigene to $170.00 and set an “overweight” rating for the company in a research note on Thursday, February 28th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $180.19.
COPYRIGHT VIOLATION WARNING: “Howard Liang Sells 1,800 Shares of Beigene Ltd (BGNE) Stock” was originally reported by Rockland Register and is owned by of Rockland Register. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://rocklandregister.com/2019/06/01/beigene-ltd-bgne-cfo-howard-liang-sells-1800-shares.html.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Article: Roth IRA
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.